Montelukast, a selective leukotriene receptor antagonist, is recommended in guidelines for
the treatment of asthma in both children and adults. However, its effectiveness is debated …

Montelukast is a leukotriene receptor antagonist (LTRA) commonly prescribed for asthma,
allergic rhinitis and sleep-related breathing disorders. Recently, some studies have reported …

Introduction Montelukast is a medicine indicated for use in asthma. Psychiatric disorders
including nightmares have not been described in clinical trials but during recent years have …

Objective Montelukast is a leukotriene receptor antagonist administered orally once daily for
treatment of chronic asthma in adults and children. A comprehensive analysis of safety data …

Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is
recommended as an alternative treatment for asthma in children with mild persistent …

Although montelukast is generally well tolerated, postmarketing studies have reported
serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food …

Background: Montelukast, a leucotriene receptor antagonist, binds the cysteinyl leucotriene
type 1 receptor. Montelukast is commonly prescribed to asthma patients as add-on therapy …

Background: The United States Food and Drug Administration issued a black box warning
on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk …

Purpose A signal has been raised concerning montelukast and adverse drug reactions
(ADRs) in children. The purpose of the present study was to evaluate psychiatric ADRs …

Background Recent observational studies suggest that the leukotriene receptor antagonist
montelukast may have neuropsychiatric adverse effects; however, results are conflicting …